RAPT Therapeutics Inc（RAPT）财务数据RAPTRAPT Therapeutics Inc

Evaluating the bottom line, RAPT Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -85.37%, provide a clear picture of how effectively RAPT converts its operational activities into shareholder value.

In the context of the broader market, RAPT competes directly with industry leaders such as ARDX and HRMY. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, RAPT's gross margin of N/A stands against ARDX's 95.24% and HRMY's 75.81%. Such benchmarking helps identify whether RAPT Therapeutics Inc is trading at a premium or discount relative to its financial performance.

In Q3 2025, RAPT reported no revenue growth (0% YoY) and a net loss of $17.58 million, down 4.62% YoY. EPS dropped significantly by 82.85% YoY to -0.65, indicating weak financial performance.